Abstract
There are concerns about the safety of hydroxyethyl starch (HES) solutions for intensive care patients regarding possible increased mortality and increased incidence of renal impairment with associated morbidity. This large trial showed no change in primary outcome related to mortality, but an increased relative risk of 21% for the use of renal replacement therapy.
Level of evidence: 1B (individual RCT with narrow confidence intervals)